Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
about the author
Lia DeGroot
ldegroot@endpointsnews.com
author articles
Hospital groups ask Congress to reform 340B program, crack down on contract pharmacy restrictions
Last year
Pharma
FDA+
Pfizer places a dozen products on emergency order after tornado damage at North Carolina plant
Last year
Pharma
FDA’s decentralized trial guidance: PhRMA, Mayo Clinic and others seek tweaks
Last year
Pharma
FDA+
NIH taps infectious disease doctor Jeanne Marrazzo to succeed Fauci as NIAID head
Last year
People
AbbVie, Lundbeck ask FDA to revise draft guidance on migraine drugs
Last year
Pharma
FDA+
PDUFA VII: Drug application fees increase by 25% in first year of new five-year deal
Last year
FDA+
Republicans share draft bill to address drug shortages
Last year
Pharma
FDA+
As pressure mounts to take action on drug shortages, lawmakers seek to boost production in the US
Last year
Pharma
FDA+
House, Senate committees mark up PBM bills as momentum for reform mounts
Last year
Pharma
FDA+
Boehringer Ingelheim, Eli Lilly's Jardiance nabs approval in Europe for chronic kidney disease
Last year
Pharma
FDA+
FDA approves Verrica's skin infection treatment, enters into non-binding term sheet for $125M loan
Last year
Pharma
FDA+
Damaged Pfizer plant remains closed as worries mount about shortages of sterile injectables
Last year
Manufacturing
FTC cautions against relying on its past PBM advocacy as industry pushes back
Last year
Pharma
FDA+
Despite Dem opposition, House committee advances pandemic preparedness bill sans drug shortage provisions
Last year
Pharma
FDA+
EMA to drug developers on AI: Carry out thorough risk assessments
Last year
AI
Pharma
House greenlights psychedelic research in NDAA, drug shortage and PBM reforms to come
Last year
Pharma
FDA+
FDA drafts new guidance on manufacturing cell and gene therapies, postmarket trial noncompliance
Last year
Cell/Gene Tx
FDA+
Duke receives $50M FDA award to establish new research center
Last year
FDA+
First page
Previous page
8
9
10
11
